Key result
Watchman shows no sex-based differences in stroke or mortality outcomes versus warfarin.
Why the study?
A large registry showed differences in periprocedural outcomes of the Watchman device between males and females, prompting evaluation of 5-year event rates by sex.
Does left atrial appendage closure have sex-specific differences in reducing stroke and mortality compared to warfarin in patients with nonvalvular atrial fibrillation?
Meta-Analysis (n=2,256)
Yes
Does left atrial appendage closure have sex-specific differences in reducing stroke and mortality compared to warfarin in patients with nonvalvular atrial fibrillation?
Sex does not significantly affect the long-term safety and effectiveness of left atrial appendage closure compared to warfarin in patients with nonvalvular atrial fibrillation.
Answers are grounded in this paper and cite their sources.
Supports Watchman use irrespective of sex in nonvalvular AF; confirms no treatment-by-sex interaction in randomized data.
BackgroundA recent analysis of a large registry showed differences in periprocedural outcomes of the Watchman left atrial appendage closure device in males compared with females. The objective of our study was to investigate the 5-year event rate in males and females enrolled in the Watchman device premarket clinical studies submitted for US Food and Drug Administration review.MethodsWe conducted a patient-level meta-analysis of 2256 patients from 4 studies: the PROTECT AF (Embolic Protection in Patients with Atrial Fibrillation) and PREVAIL (Prospective Randomized Evaluation of the Watchman Left Atrial Appendage Closure Device in Patients with Atrial Fibrillation vs Long-Term Warfarin Therapy) randomized controlled trials and their continued-access registries—CAP1 (Continued Access to PROTECT AF) and CAP2 (Continued Access to PREVAIL). The outcomes evaluated were ischemic stroke (IS), IS/systemic embolism, hemorrhagic stroke (HS), and all-cause mortality. Mixed-effects Cox regression models and statistical testing for treatment-by-sex interaction were used to compare left atrial appendage closure vs warfarin in males and females. Hazard ratios adjusted (aHRs) for CHADS2 scores were generated using the same model with CHADS2 score as a covariate. Time-to-event end points were evaluated using the Kaplan-Meier method and log-rank test.ResultsFor Watchman vs warfarin in the 2 randomized controlled trials, there was no significant interaction between sex and treatment for IS, IS/systemic embolism, HS, and all-cause mortality (P > .05); both males and females in the Watchman group had a lower aHR for HS than that in the warfarin group, which was statistically significant for males (aHR, 0.163; 95% CI, 0.045-0.593). In addition, there were no differences in outcomes between females and males treated with the Watchman device when pooling all studies.ConclusionsThese data suggest that sex does not significantly affect the long-term safety and effectiveness of the Watchman device in patients with nonvalvular atrial fibrillation; however, further studies are needed.
No takes yet. Share an insight, caveat, or question.
Jiang et al. (2023) conducted a meta-analysis in nonvalvular atrial fibrillation (n=2,256). Watchman left atrial appendage closure vs. Warfarin was evaluated on Ischemic stroke, ischemic stroke/systemic embolism, hemorrhagic stroke, and all-cause mortality (p=>.05). The Watchman left atrial appendage closure device showed no significant treatment-by-sex interaction for stroke, systemic embolism, or mortality compared to warfarin.
Synapse has enriched 10 related papers. Consider them for comparative context: